Zhou K, Wang T, Pan L, Xu W, et al. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. Ann Hematol 2024 Jun 18. doi: 10.1007/s00277-024-05823.
PMID: 38888616